EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force

Sylwia Bujkiewicz, Oriana Ciani, Bart Heeg, Dawn Lee, Jeanette M Kusel, Kristian Thorlund, Petros Pechlivanoglou, Stephen Stefani, Wanrudee Isaranuwatchai, Marc Buyse, Mario Ouwens

Value in Health · 2026-05 · 29 (5) · 711-724

DOI: 10.1016/j.jval.2026.01.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-05. Verfasst von Sylwia Bujkiewicz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics Research Group, Division of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Biomarkers, Decision Making, Endpoint Determination. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Leicester Biomedical Research Centre, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Surrogate endpoints are frequently used as primary outcomes in clinical trials. This is appropriate when they are validated for their ability to predict clinical benefit measured on patient-relevant target outcome(s). Such validation is often lacking, thus increasing uncertainty in the decision-making process of regulatory bodies, health technology assessment agencies and payers. This ISPOR Task Force Report provides recommendations on best practices for surrogate endpoint evaluation for health technology assessment decision making. It covers methods that address the 3 levels of evidence for surrogate endpoint validation described in several methodological guidelines: (1) association between treatment effects on the surrogate and the target outcome, (2) association between the surrogate and the target outcome, and (3) biological plausibility. Statistical methods for surrogate endpoint evaluation include meta-analytic approaches using individual participant data or aggregate data. Multivariate meta-analytic models are recommended because they account for the within-study correlation and estimation errors. Issues with limited data and generalizability might be addressed through Bayesian approaches for information sharing from different treatments, treatment classes or indications. Real-world data can complement randomized controlled trial data, especially in rare diseases, but require careful consideration of underlying bias. For plausibility of health economic modeling, the surrogacy analysis and the health economic model should be aligned. The modeled time course of surrogate and target outcomes per treatment arm, as well as the modeled relative effects, should be reported to assess plausibility. Parameter and structural uncertainty in surrogate relationships can be explored through scenario analyses, probabilistic sensitivity analyses, value of information analyses, and threshold analysis techniques.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalBiomarkersDecision MakingEndpoint DeterminationHumansAdvisory CommitteesBayes TheoremMeta-Analysis as TopicResearch Design

Stichwörter der Autor:innen

outcomes researchsurrogate endpointsvalidation

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Biostatistics Research Group, Division of Public Health and Epidemiology, School of Medical Sciences, University of Leicester, Leicester, UK.
  • Center for Research on Health and Social Care Management, SDA Bocconi School of Management, Milan, Italy. Electronic address: oriana.ciani@unibocconi.it.
  • National Health Care Institute, Diemen, The Netherlands.
  • Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, England, UK.
  • National Institute for Health and Care Excellence, London, England, UK.
  • Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

Förderung

  • NIHR Leicester Biomedical Research Centre
  • Medical Research Council

Zitieren

APA

Bujkiewicz, S., Ciani, O., Heeg, B., Lee, D., Kusel, J. M., Thorlund, K., Pechlivanoglou, P., Stefani, S., Isaranuwatchai, W., Buyse, M., & Ouwens, M. (2026). Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force. Value in Health, 29(5), 711-724. https://doi.org/10.1016/j.jval.2026.01.020

Vancouver

Bujkiewicz S, Ciani O, Heeg B, Lee D, Kusel JM, Thorlund K, et al. Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force. Value in Health. 2026;29(5):711-724. doi:10.1016/j.jval.2026.01.020

BibTeX
@article{Bujkiewicz2026,
  author = {Bujkiewicz, Sylwia and Ciani, Oriana and Heeg, Bart and Lee, Dawn and Kusel, Jeanette M and Thorlund, Kristian and Pechlivanoglou, Petros and Stefani, Stephen and Isaranuwatchai, Wanrudee and Buyse, Marc and Ouwens, Mario},
  title = {Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {5},
  pages = {711--724},
  doi = {10.1016/j.jval.2026.01.020}
}
Kostenlos starten →